|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600125973 |
|
最近更新日期: Date of Last Refreshed on: |
2026-06-01 22:19:16 |
|
注册时间: Date of Registration: |
2026-06-01 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
SPP1-CD44-PI3K/AKT 信号轴介导铁死亡在黄韧带肥厚纤维化中的机制研究 |
|
Public title: |
Mechanistic Study of Ferroptosis Mediated by the SPP1-CD44-PI3K/AKT Signaling Axis in Ligamentum Flavum Hypertrophy and Fibrosis |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
SPP1-CD44-PI3K/AKT 信号轴介导铁死亡在黄韧带肥厚纤维化中的机制研究 |
|
Scientific title: |
Mechanistic Study of Ferroptosis Mediated by the SPP1-CD44-PI3K/AKT Signaling Axis in Ligamentum Flavum Hypertrophy and Fibrosis |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
曲小辰 |
研究负责人: |
曲小辰 |
|
Applicant: |
Xiaochen Qu |
Study leader: |
Qu Xiaochen |
|
申请注册联系人电话: Applicant telephone: |
+86 180 9887 0531 |
研究负责人电话:
Study leader's |
+86 411 8363 5963 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
xiaochen13@hotmail.com |
研究负责人电子邮件: Study leader's E-mail: |
quxiaochen@firsthosp-dmu.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
大连市西岗区中山路222号 |
研究负责人通讯地址: |
大连市西岗区中山路222号 |
|
Applicant address: |
Zhongshan Road 222,Dalian |
Study leader's address: |
Zhongshan Road 222,Dalian |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
大连医科大学附属第一医院 |
||
|
Applicant's institution: |
Dalian Medical University First Affiliated Hospital |
||
|
研究负责人所在单位: |
大连医科大学附属第一医院 |
||
|
Affiliation of the Leader: |
The First Affiliated Hospital of Dalian Medical University |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
PJ-KS-KY-2026-670 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
大连医科大学附属第一医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of The First Affiliated Hospital of Dalian Medical University |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-05-14 00:00:00 | ||
|
伦理委员会联系人: |
徐蕾 |
||
|
Contact Name of the ethic committee: |
Xu Lei |
||
|
伦理委员会联系地址: |
大连市西岗区中山路222号 |
||
|
Contact Address of the ethic committee: |
Zhongshan Road 222,Dalian |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 411 8301 0706 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
dyyyirb@163.com |
|
研究实施负责(组长)单位: |
大连医科大学附属第一医院 |
||||||||||||||||||||||
|
Primary sponsor: |
The First Affiliated Hospital of Dalian Medical University |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
大连市西岗区中山路222号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Zhongshan Road 222,Dalian |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
辽宁省科技计划联合计划 |
||||||||||||||||||||||
|
Source(s) of funding: |
Department of Science and Technology of Liaoning Province |
||||||||||||||||||||||
|
研究疾病: |
黄韧带肥厚 |
||||||||||||||||||||||
|
Target disease: |
Thickened ligamentum flavum |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
探讨SPP1是否通过CD44-PI3K通路诱导铁死亡并促进黄韧带成纤维细胞纤维化,为黄韧带肥厚机制及潜在干预靶点提供依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
To explore whether SPP1 induces ferroptosis and promotes fibrosis of ligamentum flavum fibroblasts through the CD44-PI3K signaling pathway, so as to provide a basis for the mechanism of ligamentum flavum hypertrophy and potential intervention targets. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.经影像学(MRI/CT)及临床诊断明确为腰椎管狭窄症(LSS)伴黄韧带肥厚的患者; 2.手术中切除黄韧带组织并可获得足量标本,用于细胞分离培养或组织学检测; 3.患者年龄 40-60 岁 (包括两端); 4.无严重感染或系统性疾病影响实验结果; 5.患者知情同意并签署知情同意书。 |
||||||||||||||||||||||
|
Inclusion criteria |
1.Patients who have been diagnosed with lumbar spinal stenosis (LSS) accompanied by thickening of the ligamentum flavum through imaging (MRI/CT) and clinical diagnosis; 2.During the operation, ligamentum flavum tissue is removed and sufficient specimens can be obtained for cell isolation and culture or histological detection; 3. Patients aged 40-60 years (inclusive); 4. No severe infection or systemic diseases affecting experimental results; 5. Patients are informed and have signed the informed consent form. |
||||||||||||||||||||||
|
排除标准: |
1.合并脊柱肿瘤、结核、化脓性感染等疾病者; 2.合并类风湿关节炎、强直性脊柱炎、系统性红斑狼疮等自身免疫性疾病者; 3.合并严重代谢性骨病(如甲状旁腺功能异常、骨软化等)或长期影响骨/韧带代谢的疾病; 4.有明显脊柱外伤史或既往腰椎手术史; 5.长期使用激素、免疫抑制剂或抗肿瘤药物者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1.Those with concurrent diseases such as spinal tumors, tuberculosis, and purulent infections; 2.Patients complicated with autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis and systemic lupus erythematosus; 3. Concurrent severe metabolic bone diseases (such as parathyroid dysfunction, osteomalacia, etc.) or diseases that have long-term effects on bone/ligament metabolism; 4. History of significant spinal trauma or previous lumbar surgery; 5. Long-term use of steroids, immunosuppressants, or antitumor drugs. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-06-01 00:00:00至 To 2028-06-22 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-06-01 00:00:00 至 To 2028-06-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
无 |
|
Blinding: |
None |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
本研究已选择不进行数据共享,无对外共享原始数据的方式与途径。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
This study has chosen not to share data, and there are no ways or channels to share the original data externally. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究为体外细胞实验,实验相关指标数据均由本课题组在本实验室统一采集、现场记录;所有原始实验数据、图片及统计结果及时归档保存,建立专属实验数据台账。数据录入双人核对,确保真实、完整、可溯源。实验资料及原始数据按科研档案管理规范妥善留存,严格保密,仅用于本课题学术研究,不对外泄露及挪作他用。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
This research is an in vitro cell experiment. All the relevant index data of the experiment were uniformly collected and recorded on-site by our research group in our laboratory. All original experimental data, images and statistical results are promptly archived and preserved, and a dedicated experimental data ledger is established. Data entry is double-checked by two people to ensure its authenticity, completeness and traceability. Experimental data and original data are properly retained in accordance with the management norms of scientific research archives, strictly kept confidential, and are only used for academic research on this topic. They are not disclosed to the outside or misappropriated for other purposes. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |